Additional file 1 of Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer

Supplementary Material

MOESM1 of INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression

Additional file 1: Figure S1. INAVA regulates PTC cell metastasis. Metastasis area was calculated using Image J software in HE stained sections

Table_1_Decreased circulating dipeptidyl peptidase-4 activity after short-term intensive insulin therapy predicts clinical outcomes in patients with newly diagnosed type 2 diabetes.docx

BackgroundThis study aims to investigate the changes in circulating dipeptidyl peptidase-4 (DPP-4) activity following short-term intensive insulin therapy (SIIT) in newly diagnosed type 2 diabetes (T2D) patients and to assess its potential in predicting long-term remission.MethodsNinety-five patients underwent SIIT for 2-3 weeks to attain and sustain near-normal glycemia. Insulin was then discontinued, and patients were followed for a year to evaluate glycemic outcomes. Biochemical tests, serum DPP-4 activity, and mixed meal tolerance tests were conducted at baseline, post-SIIT, and the 3-month follow-up.ResultsDPP-4 activity decreased from 44.08 ± 9.58 to 40.53 ± 8.83 nmol/min/mL after SIIT (PConclusionCirculating DPP-4 activity significantly decreases after SIIT. The change in circulating DPP-4 activity during the 3-month post-treatment phase has the potential to predict long-term remission.</p

Additional file 1 of Genome-wide analysis study of gestational diabetes mellitus and related pathogenic factors in a Chinese Han population

Supplementary Material

Correction of Diabetic Erectile Dysfunction with Adipose Derived Stem Cells Modified with the Vascular Endothelial Growth Factor Gene in a Rodent Diabetic Model

<div><p>The aim of this study was to determine whether adipose derived stem cells (ADSCs) expressing vascular endothelial growth factor (VEGF) gene can improve endothelial function, recover the impaired VEGF signaling pathway and enhance smooth muscle contents in a rat diabetic erectile dysfunction (DED) model. DED rats were induced via intraperitoneal injection of streptozotocin (40 mg/kg), and then screened by apomorphine (100 µg/kg). Five groups were used (n = 12/group)–Group 1 (G1): intracavernous injection of lentivirus-VEGF; G2: ADSCs injection; G3: VEGF-expressing ADSCs injection; G4: Phosphate buffered saline injection; G1–G4 were DED rats; G5: normal rats. The mean arterial pressure (MAP) and intracavernosal pressure (ICP) were measured at days 7 and 28 after the injections. The components of the VEGF system, endothelial, smooth muscle, pericytes markers in cavernoursal tissue were assessed. On day 28 after injection, the group with intracavernosum injection of ADSCs expressing VEGF displayed more efficiently and significantly raised ICP and ICP/MAP (<i>p</i><0.01) than those with ADSCs or lentivirus-VEGF injection. Western blot and immunofluorescent analysis demonstrated that improved erectile function by ADSCs-VEGF was associated with increased expression of endothelial markers (VEGF, VEGF R1, VEGF R2, eNOS, CD31 and vWF), smooth muscle markers (a-actin and smoothelin), and pericyte markers (CD146 and NG2). ADSCs expressing VEGF produced a therapeutic effect and restored erectile function in diabetic rats by enhancing VEGF-stimulated endothelial function and increasing the contents of smooth muscle and pericytes.</p></div

Physiologic and metabolic parameters after 4 weeks treatment.

<p>STZ injection led to a significant stable increase of random blood glucose level (A) and body weight loss (B) in the diabetic rats compared to age-matched non-diabetic controls. *<i>p</i><0.05, body weight of normal rats control at day 28 <i>versus</i> other group rats; **<i>p</i><0.01. Both of the blood glucose concentration and body weights in diabetic rats were not affected by either treatment including VEGF or ADSCs or ADSCs-VEGF injection into the cavernous of DED rats.</p

Study flowchart for patients enrollment.

<p>Study flowchart for patients enrollment.</p

ADSCs-VEGF ameliorated pericytes markers in the cavernous tissue of DED rats.

<p>Immunofluorescent staining (A) and hemi-quantitative analysis (B) showed decreased pericytes markers (CD146, NG2) in the penis of STZ-induced DED rats treated by PBS compared with age-matched normal rats. And ADSCs or lentivirus-VEGF treatment partly but ADSCs-VEGF showed more effectively recovery of these markers. Scale bar = 50 um; *<i>p</i><0.05, **<i>p</i><0.01.</p

ADSCs -VEGF increased the expression of VEGF, its two receptors, and eNOS in STZ-induced diabetic rats.

<p>Expression of VEGF, its receptors VEGF R1 and VEGF R2, and eNOS increased in STZ-induced rats 4 weeks after ADSCs with or without VEGF or lentivirus-VEGF alone confirmed by immunofluorescence staining (white arrow represents specific staining) (<b>A</b>), Western blotting (<b>B</b>), and quantitative analysis for Western blotting (<b>C</b>). Expression was higher in the ADSCs-VEGF treatment group than with ADSCs or VEGF treatment, but no difference between ADSCs and lentivirus-VEGF treatment (<b>A–C</b>). VEGF, VEGFR1, VEGFR2 and eNOS expression were greater at 28 days after all three treatments than in 7 days (<b>B, C</b>). Scale bar = 50 µm; *<i>p</i><0.05, **<i>p</i><0.01.</p

ADSCs-VEGF injection improved erectile function in streptozotocin (STZ)-induced diabetic rats.

<p>A: Representative intracavernous pressure (ICP) tracing response to the stimulation of the cavernous nerve (1.5 mA, 20 Hz, and duration of 50 s) in STZ-induced diabetic rats at 4 weeks after intracavernous injection of lentivirus-VEGF, ADSCs, ADSCs-VEGF; or untreated STZ-induced diabetic rats, and age-matched control rats. The stimulus interval (50 s) was indicated by a horizontal bar. B: The effects of treatment with ADSCs or VEGF or ADSCs-VEGF on the increase of ICP by the time. C: The ratio of total ICP to MAP was calculated for each group (n = 6). *<i>p</i><0.05, **<i>p</i><0.01. ICP = intracavernous pressure; MAP = mean arterial pressure.</p